Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

IRLAB Therapeutics – executive interview

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — 7 videos in collection

More on this equity

Based in Sweden, IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD) and other CNS disorders. Its two lead assets are mesdopetam (D3-receptor antagonist for levodopa-induced dyskinesias in PD) and pirepemat (PFC enhancer for impaired balance and falls). Mesdopetam is an oral D3 antagonist and has just completed recruitment in a Phase IIb trial for levodopa-induced dyskinesias in PD, with top-line data anticipated around year end. Pirepemat is an oral prefrontal cortex enhancer in a Phase IIb trial for the treatment of impaired balance and falls in PD. IRLAB is also developing a preclinical pipeline of drug candidates (IRL942 and IRL757) for the non-motor symptoms of PD and a potential once-daily treatment for PD without complications (P003). The company remains well funded in the medium term.

In this video, CEO Richard Godfrey provides an update on IRLAB’s pipeline and upcoming milestones.

< Previous
Next >

You may also be interested in these:

Healthcare

IRLAB Therapeutics – executive interview

Healthcare

IRLAB Therapeutics – executive interview
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.